FDA Approves Pylarify TruVu to Expand PSMA-PET Imaging Access for Prostate Cancer
Food and Drug Administration approved Pylarify TruVu, improving PSMA-PET availability and reliability, enabling better prostate cancer staging, earlier recurrence detection, and broader access to advanced diagnostic imaging.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.